Business Context and Reporting Period
This Form 8-K Current Report, dated January 7, 2026, covers corporate governance and administrative updates for LeonaBio, Inc. (formerly Athira Pharma, Inc.). The report details a corporate name change, a ticker symbol update, and executive compensation adjustments effective in early January 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate structural changes and executive agreements.
Material Changes Versus Prior Period
- Corporate Name: Effective January 9, 2026, the company changed its name from Athira Pharma, Inc. to LeonaBio, Inc.
- Trading Symbol: Effective January 12, 2026, the ticker symbol on The Nasdaq Capital Market changed to "LONA".
- Executive Compensation: On January 7, 2026, the Board approved a salary increase for Chief Financial Officer Robert Renninger to $460,000 annually, effective retroactively to December 16, 2025.
- Executive Agreements: On January 8, 2026, the company entered into an Amended and Restated Change in Control and Severance Agreement with Mr. Renninger.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, forward-looking revenue projections, or management commentary regarding business strategy or market outlook. The document notes the launch of a new corporate website (www.leonabio.com) and lists social media channels used for investor communications. It clarifies that the name and symbol changes do not affect stockholder rights or the company's CUSIP number.
Severance Agreement Details
The new agreement with CFO Robert Renninger outlines specific benefits upon termination without "cause" or for "good reason":
- Outside Change in Control Period: 75% of annual base salary and up to 9 months of COBRA coverage.
- During Change in Control Period: 100% of annual base salary, 100% of target annual bonus, up to 12 months of COBRA coverage, and 100% accelerated vesting of service-based equity awards.
Investor Verification Checklist
- Verify the new ticker symbol "LONA" is active on The Nasdaq Capital Market as of January 12, 2026.
- Confirm the updated corporate name "LeonaBio, Inc." in brokerage accounts and trading platforms.
- Review the full text of the Amended and Restated Change in Control and Severance Agreement (Exhibit 10.1) for specific definitions of "cause" and "good reason."
- Check the new corporate website (www.leonabio.com) for updated investor relations materials and press releases.